MEASuRE: Metreleptin Effectiveness And Safety Registry

Launched by AEGERION PHARMACEUTICALS, INC. · Dec 22, 2014

Keywords

ClinConnect Summary

The MEASuRE study is a clinical trial designed to collect information on the effectiveness and safety of a medication called metreleptin, which is used to treat certain conditions related to lipodystrophy—this is when the body has trouble storing fat properly. The trial is open to patients who are already receiving metreleptin or have recently finished a clinical study and wish to continue the treatment. It aims to gather insights from patients across the U.S. and Europe who are using this medication.

To participate, individuals must be currently treated with metreleptin or have been treated in the past and be willing to provide written consent. However, those taking part in other clinical trials with experimental treatments cannot join this registry. Participants in the MEASuRE study can expect to provide information about their experiences with metreleptin, contributing to a better understanding of how this medication works in real-life settings. This is a voluntary registry, meaning patients can choose whether or not to take part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients treated with metreleptin through commercial supply at the time or before enrolment into registry
• • Patients who provide a written consent
• • Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply
• Exclusion Criteria:
• • • Patients currently treated with an investigational agent as part of a clinical trial